Version July 2025
Dosage guidance:
Dosing: Errors have occurred due to clinician misinterpretation of dosing information and units. Maintenance dose is expressed as mcg/kg/hour (Ref).
Clinical considerations: Does not provide adequate and reliable amnesia; therefore, use of additional agents with amnestic properties (eg, benzodiazepines, propofol) may be necessary.
Agitation associated with schizophrenia or bipolar I or II disorder (alternative agent):
Note: Some experts recommend reserving use for patients with mild or moderate agitation who cannot tolerate first-line treatments (Ref). Monitor vital signs including orthostatic measures after each dose to prevent falls and syncope. Due to risk of hypotension, additional half-doses are not recommended in patients with systolic blood pressure (SBP) <90 mm Hg, diastolic blood pressure (DBP) <60 mm Hg, heart rate <60 beats per minute, or postural decrease in SBP ≥20 mm Hg or in DBP ≥10 mm Hg. Patients should not perform activities that require mental alertness (eg, operating machinery, driving) for at least 8 hours after administration.
Mild or moderate agitation: Sublingual film: Sublingual/Buccal: Initial: 120 mcg; if agitation persists, up to 2 additional doses of 60 mcg may be administered at least 2 hours apart. Maximum: 240 mcg/day.
Severe agitation: Sublingual film: Sublingual/Buccal: Initial: 180 mcg; if agitation persists, up to 2 additional doses of 90 mcg may be administered at least 2 hours apart. Maximum: 360 mcg/day.
General anesthesia, maintenance (adjunctive agent) (off-label use):
Note: May reduce sedative-hypnotic and/or opioid requirements of general anesthesia; may reduce postoperative opioid requirements (Ref).
Continuous IV infusion: Usual dosage range: 0.1 to 0.8 mcg/kg/hour; titrate to desired effect (Ref).
Procedural sedation or monitored anesthesia care (including flexible scope intubation [awake]):
IV: Initial: Loading dose of 0.5 to 1 mcg/kg over 10 minutes (use lower range for less invasive procedures [eg, ophthalmic]), followed by a continuous infusion of 0.2 to 1 mcg/kg/hour; titrate to desired level of sedation.
Sedation, critically ill:
Note: Deep sedation is not achievable with dexmedetomidine monotherapy (Ref).
IV:
Loading dose (optional): Note: Not recommended due to concerns for hemodynamic compromise (eg, hypertension, hypotension, bradycardia) (Ref).
Initial: 1 mcg/kg over 10 minutes, followed by a continuous infusion.
Continuous infusion: Usual dosage range: 0.2 to 1.5 mcg/kg/hour; titrate by 0.2 mcg/kg/hour every 30 minutes to sedation goal (eg, Richmond Agitation Sedation Scale score 0 to -2) or clinical effect (eg, ventilator synchrony) (Ref).
Note: Although infusion rates as high as 2.5 mcg/kg/hour have been used, doses >1.5 mcg/kg/hour do not provide additional clinical efficacy (Ref). Manufacturer recommends that infusion duration not exceed 24 hours; however, randomized clinical trials have demonstrated efficacy and safety up to ~14 days (Ref). Withdrawal symptoms (eg, hypertension, tachycardia, delirium, agitation) may be more likely to occur in patients with a history of hypertension or those receiving dexmedetomidine for longer durations, at greater cumulative doses (eg, >12 mcg/kg/day), or higher peak rates (eg, >0.8 mcg/kg/hour). In such patients, avoid abrupt discontinuation; carefully decrease dose, while monitoring for withdrawal symptoms (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Altered kidney function: No dosage adjustment necessary for any degree of kidney dysfunction (Ref).
Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzed (highly protein bound): No supplemental dose or dosage adjustment necessary (Ref).
Peritoneal dialysis: Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (Ref).
CRRT: No dosage adjustment necessary (Ref).
PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).
The liver dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, FCCP; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.
Liver impairment prior to treatment initiation:
Initial or dose titration in patients with preexisting liver cirrhosis:
IV:
Note: Dexmedetomidine undergoes extensive hepatic metabolism via glucuronidation, which is highly dependent on liver blood flow. In the setting of severe liver insufficiency, clearance was reduced by ~50% (Ref). Accumulation is expected in the setting of advanced liver impairment (Ref).
Child-Turcotte-Pugh class A and B: No dosage adjustment necessary (Ref).
Child-Turcotte-Pugh class C:
General anesthesia, ICU sedation: Use lowest end of the recommended dosage range; titrate to desired effect (Ref).
Procedural sedation or monitored anesthesia care:
Loading dose: No dosage adjustment necessary (Ref).
Continuous infusion: Reduce dose to 0.1 to 0.5 mcg/kg/hour; titrate to desired level of sedation (Ref).
Sublingual film: Agitation associated with schizophrenia or bipolar I or II disorder (Ref):
Note: Monitor vital signs, including orthostatic measures, after each dose to prevent falls and syncope. Due to risk of hypotension, use of additional doses following the initial dose is not recommended in patients with systolic blood pressure (SBP) <90 mm Hg, diastolic blood pressure (DBP) <60 mm Hg, heart rate <60 beats per minute, or postural decrease in SBP ≥20 mm Hg or in DBP ≥10 mm Hg. Patients should not perform activities that require mental alertness (eg, operating machinery, driving) for at least 8 hours after administration.
Child-Turcotte-Pugh class A and B:
Mild or moderate agitation: Initial: 90 mcg; if agitation persists, up to 2 additional doses of 60 mcg may be administered at least 2 hours apart. Maximum: 210 mcg/day.
Severe agitation: Initial: 120 mcg; if agitation persists, up to 2 additional doses of 60 mcg may be administered at least 2 hours apart. Maximum: 240 mcg/day.
Child-Turcotte-Pugh class C:
Mild or moderate agitation: Initial: 60 mcg; if agitation persists, up to 2 additional doses of 60 mcg may be administered at least 2 hours apart. Maximum: 180 mcg/day.
Severe agitation: Initial: 90 mcg; if agitation persists, up to 2 additional doses of 60 mcg may be administered at least 2 hours apart. Maximum: 210 mcg/day.
The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.
Class 1, 2, or 3 obesity (BMI ≥30 kg/m2):
IV: Use adjusted body weight for initial weight-based dose calculations, then titrate to clinical effect (Ref). Clinicians should not change dosing weight from one weight metric to another during therapy (ie, adjusted body weight to/from actual body weight) (Ref). Refer to adult dosing for indication-specific doses.
Rationale for recommendations:
There are limited data on the effects of obesity on dexmedetomidine dosing or pharmacokinetics. Pharmacokinetic studies evaluating dexmedetomidine, a lipophilic compound, have shown a meaningful correlation between both fat free mass (FFM) and lean body weight (LBW) with clearance, but not between actual body weight and clearance (Ref). For Vd, defining the most descriptive weight metric is less clear, but dexmedetomidine appears to have a small additive volume above FFM and LBW (Ref).
Some data suggest using LBW for initial weight-based dosing of dexmedetomidine (Ref); however, there are concerns with calculation errors when using the complex LBW and FFM formula, especially in critical situations (Ref). In addition, if LBW is used, underdosing may occur in clinical situations where faster sedation is indicated (eg, procedural sedation, induction of anesthesia, ICU sedation) (Ref). Using actual body weight in weight-based dosing calculations for bolus doses or continuous infusions may lead to excessive concentrations resulting in adverse effects (Ref). Use of an alternative size descriptor (ie, adjusted body weight) is recommended for dosing in patients with class 1, 2, or 3 obesity (BMI ≥30 kg/m2) (Ref).
Agitation associated with schizophrenia or bipolar I or II disorder:
Note: Monitor vital signs including orthostatic measures after each dose to prevent falls and syncope. Due to risk of hypotension, additional half-doses are not recommended in patients with systolic blood pressure (SBP) <90 mm Hg, diastolic blood pressure (DBP) <60 mm Hg, heart rate <60 beats per minute, or postural decrease in SBP ≥20 mm Hg or in DBP ≥10 mm Hg. Patients should not perform activities that require mental alertness (eg, operating machinery, driving) for at least 8 hours after administration.
Mild, moderate, or severe agitation: Sublingual film: Sublingual/Buccal: Initial: 120 mcg; if agitation persists, up to 2 additional doses of 60 mcg may be administered at least 2 hours apart. Maximum: 240 mcg/day.
Mechanically ventilated patients in the ICU, sedation: IV: Refer to adult dosing. Consider dosage reduction. No specific guidelines available. Dose selections should be cautious, at the low end of dosage range; titration should be slower, allowing adequate time to evaluate response.
Procedural sedation or monitored anesthesia care (including flexible scope intubation [awake]): IV: Refer to adult dosing: Initial: Loading dose of 0.5 mcg/kg over 10 minutes; Maintenance infusion: Dosage reduction should be considered.
(For additional information see "Dexmedetomidine: Pediatric drug information")
Dosage guidance:
Dosing: Errors have occurred due to misinterpretation of dosing information. Maintenance dose expressed as mcg/kg/ hour. Individualize and titrate to desired clinical effect.
Safety: Consult local regulations and individual institutional policies and procedures; should only be used by experienced personnel who are not actively engaged in the procedure or surgery.
ICU sedation: Limited data available:
Infants, Children, and Adolescents:
Loading dose (Optional): IV: 0.5 to 1 mcg/kg/dose over 10 minutes; use of loading dose is dependent upon concomitant sedation agents and patient's current and desired level of sedation (Ref).
Maintenance dose: Note: Although the manufacturer recommends limiting continuous infusions to ≤24 hours in adult patients, duration in pediatric patients has been reported from 2 hours to 103 days; weaning of dexmedetomidine and/or replacement strategies have been recommended (Ref).
Continuous IV infusion: Initial: 0.2 to 0.5 mcg/kg/hour; increase dose by 0.1 to 0.3 mcg/kg/hour to achieve desired level of sedation; usual dose range: 0.2 to 2.5 mcg/kg/hour (Ref). Note: Infants may require higher maintenance infusion rates than either neonates or older children (Ref).
Junctional ectopic tachycardia, postoperative; prevention : Limited data available; dosing regimens variable; optimal dose not established:
Infants, Children, and Adolescents (very limited data for adolescents) (Ref):
Loading dose: 0.5 to 1 mcg/kg as a single dose over 15 to 20 minutes; infusion should be completed 10 minutes prior to anesthesia induction.
Continuous IV infusion: 0.5 to 0.75 mcg/kg/hour; administer immediately following loading dose and continue intraoperatively and postoperatively for 48 hours.
Sedation, noninvasive procedures; nonintubated (nonpainful or minimally painful):
Intranasal: Limited data available; reported dosing regimens variable and ideal dose not established:
Infants and Children (very limited data in children >10 years): Intranasal: Usual dose: 2 to 3 mcg/kg as a single dose 30 to 60 minutes prior to procedure; reported dose range: 1 to 4 mcg/kg; dosing based on multiple studies evaluating intranasal dexmedetomidine administered prior to procedures (eg, CT, MRI, transesophageal echocardiography, ophthalmic exams, auditory brainstem response [brainstem auditory evoked response] test) (Ref).
IM: Limited data available; reported dosing regimens variable and ideal dose not established:
Infants, Children, and Adolescents: IM: Initial dose: 1 to 4 mcg/kg as a single dose prior to procedure; if sedation inadequate, may give a second dose of 1 to 2 mcg/kg; dosing based on multiple studies evaluating intramuscular dexmedetomidine administered prior to procedures (eg, CT, MRI, EEG) (Ref).
IV:
Infants, Children, and Adolescents:
Loading dose: IV: Usual dose: 1 to 2 mcg/kg/dose over 10 minutes; may repeat if sedation is inadequate; reported range: 0.5 to 3 mcg/kg/dose (Ref). Note: A lower loading dose may be needed when administered with concomitant anesthetics, sedatives, hypnotics, or opioids (eg, 0.5 to 1 mcg/kg) (Ref).
Maintenance dose: Continuous IV infusion: Usual dose range: 1 to 2 mcg/kg/hour; titrate to achieve clinical effect; reported range: 0.5 to 2 mcg/kg/hour (Ref). Note: Lower doses have been reported when administered concomitantly with midazolam or propofol (Ref).
Sedation, pre-anesthetic: Limited data available:
Intranasal:
Children and Adolescents (very limited data available in patients >9 years): Intranasal: 1 to 2 mcg/kg as a single dose 30 to 60 minutes prior to induction of anesthesia. Higher-end doses (2 mcg/kg) are recommended for older children (≥5 years) and adolescents (Ref).
Oral: Dosing regimens variable; optimal dose not established:
Children and Adolescents (very limited data available in adolescents): Oral: 1 to 4 mcg/kg as a single dose 45 minutes prior to induction of anesthesia; dosing based on three retrospective studies and one prospective study (Ref). Note: A dose of 1 mcg/kg has not been shown to decrease the incidence of emergence delirium (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Parenteral: There are no dosage adjustments provided in the manufacturer's labeling; however, pharmacokinetics were not significantly different in adult patients with severe renal impairment (CrCl <30 mL/minute).
Parenteral: There are no pediatric-specific dosage adjustments provided in the manufacturer's labeling; however, clearance is reduced in varying degrees based on the level of hepatic impairment; adult data suggest a dosage adjustment.
Dexmedetomidine has been associated with hypotension and/or bradycardia (Ref). Hypertension, although less common, may also occur (Ref). Bradycardia, hypotension, and hypertension have occurred in pediatric patients (Ref). Dexmedetomidine has been associated with cardiac arrest/asystole in case reports (Ref). Bradycardia, hypotension, and hypertension are all more common with the IV formulation.
Mechanism: Dexmedetomidine can cause a biphasic blood pressure response (a short hypertensive phase with hypotension thereafter). These effects are related to alpha-2 adrenergic receptor subtypes: Alpha-2B (responsible for hypertensive effects) and alpha-2A (responsible for hypotension) (Ref). In addition, dexmedetomidine decreases sinus and atrioventricular nodal function in pediatric patients (Ref).
Onset: Hypotension and/or bradycardia: Rapid. In one study, the median time to first hypotensive episode was 5 hours (range: ~3 to 13 hours) (Ref). Another study reported a median time of ~4 hours for hemodynamic instability, with more than two-thirds of patients developing hypotension and/or bradycardia within 24 hours (Ref). An additional study showed a median onset of 17 hours for the first hemodynamic event (hypotension or bradycardia) (Ref).
Risk factors:
• Hypotension and/or bradycardia:
- Low baseline arterial blood pressure (Ref)
- Increased age (Ref)
- Increased severity of illness (Ref)
- Loading dose (risk for hypotension in neurosurgical patients or risk for bradycardia in general ICU patients) (Ref)
- Inotrope use (cardiac ICU patients) (Ref)
- Coronary artery disease (Ref)
- Lack of adjuvant sedatives (Ref)
- Titration of infusion < every 30 minutes (Ref)
- Infusion >6 hours (pediatric patients) (Ref)
• Hypertension:
- Loading dose and higher peak plasma concentrations (risk for transient hypertension) (Ref)
• Cardiac arrest/asystole:
- Bradycardia or acute hypotension (Ref)
Prolonged use of dexmedetomidine use may lead to drug tolerance, tachyphylaxis, loss of sedation control, increased adverse reactions, and withdrawal syndrome (Ref). Withdrawal symptoms may occur in both adult and pediatric patients and may include hypertension, tachycardia, diaphoresis, anxiety, fever, and delirium (Ref). The incidence of withdrawal has been reported in ∼30% of patients (Ref).
Mechanism: Dose- and time-related; related to alpha-2 receptor affinity, binding, and upregulation after prolonged use (Ref).
Onset: Rapid; withdrawal symptoms typically occur with prolonged use (eg, >24 hours) (Ref). However, mild, transient withdrawal symptoms (eg, agitation, delirium) have occurred with short term use (<2 hours) in pediatric patients.
Risk factors:
• Higher cumulative daily doses (eg, >12 mcg/kg/day) or with higher peak rates (eg, >0.8 mcg/kg/hour) (Ref)
• Prolonged use (Ref)
• History of hypertension (Ref)
• Duration of concurrent opioid prior to dexmedetomidine discontinuation (Ref)
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency dependent upon dose, duration, and indication. Reported adverse reactions are for IV dexmedetomidine in adults unless otherwise noted.
>10%:
Cardiovascular: Bradycardia (infants, children, and adolescents: IV: 57% to 71%; adults: IV: 5% to 42%, sublingual: 2%;) (table 1), hypertension (infants, children, and adolescents: IV: 26% to 47%; adults: IV: 11% to 16%, sublingual: 5%) (table 2), hypotension (infants, children, and adolescents: IV: 16% to 31%; adults: IV: 24% to 56%, sublingual: 5%) (table 3), tachycardia (infants, children, and adolescents: IV: 2% to 7%; adults: 25%)
|
Drug (Dexmedetomidine) |
Comparator |
Placebo |
Population |
Dosage Form and Dose |
Indication |
Number of Patients (Dexmedetomidine) |
Number of Patients (Comparator) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|---|---|
|
71% |
N/A |
N/A |
Infants, children, and adolescents |
IV: High dose |
Sedation for magnetic resonance imaging |
38 |
N/A |
N/A |
|
57% |
N/A |
N/A |
Infants, children, and adolescents |
IV: Low dose |
Sedation for magnetic resonance imaging |
42 |
N/A |
N/A |
|
57% |
N/A |
N/A |
Infants, children, and adolescents |
IV: Middle dose |
Sedation for magnetic resonance imaging |
42 |
N/A |
N/A |
|
2% |
N/A |
0% |
Adults |
Sublingual film: 180 mcg |
Acute treatment of agitation associated with schizophrenia or bipolar I or II disorder |
252 |
N/A |
252 |
|
2% |
N/A |
0% |
Adults |
Sublingual film: 120 mcg |
Acute treatment of agitation associated with schizophrenia or bipolar I or II disorder |
255 |
N/A |
252 |
|
7% |
N/A |
3% |
Adults |
IV |
Intensive care unit sedation |
387 |
N/A |
379 |
|
5% |
Propofol: 0% |
3% |
Adults |
IV: 0.5 mcg/kg/hour (range: 0.1 to 6 mcg/kg/hour) |
Intensive care unit sedation |
798 |
188 |
400 |
|
42% |
Midazolam: 19% |
N/A |
Adults |
IV |
Long-term intensive care unit sedation |
244 |
122 |
N/A |
|
14% |
N/A |
4% |
Adults |
IV: 1.3 mcg/kg/hour (range: 0.3 to 6.1 mcg/kg/hour) |
Procedural sedation |
318 |
N/A |
113 |
|
Drug (Dexmedetomidine) |
Comparator |
Placebo |
Population |
Dosage Form and Dose |
Indication |
Number of Patients (Dexmedetomidine) |
Number of Patients (Comparator) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|---|---|
|
47% |
N/A |
N/A |
Infants, children, and adolescents |
IV: High dose |
Sedation for magnetic resonance imaging |
38 |
N/A |
N/A |
|
41% |
N/A |
N/A |
Infants, children, and adolescents |
IV: Middle dose |
Sedation for magnetic resonance imaging |
42 |
N/A |
N/A |
|
26% |
N/A |
N/A |
Infants, children, and adolescents |
IV: Low dose |
Sedation for magnetic resonance imaging |
42 |
N/A |
N/A |
|
16% |
N/A |
18% |
Adults |
IV |
Intensive care unit sedation |
387 |
N/A |
379 |
|
13% |
Propofol: 4% |
19% |
Adults |
IV: 0.5 mcg/kg/hour (range: 0.1 to 6 mcg/kg/hour) |
Intensive care unit sedation |
798 |
188 |
400 |
|
11% |
Midazolam: 15% |
N/A |
Adults |
IV |
Long-term intensive care unit sedation |
244 |
122 |
N/A |
|
13% |
N/A |
24% |
Adults |
IV: 1.3 mcg/kg/hour (range: 0.3 to 6.1 mcg/kg/hour) |
Procedural sedation |
318 |
N/A |
113 |
|
Drug (Dexmedetomidine) |
Comparator |
Placebo |
Population |
Dosage Form and Dose |
Indication |
Number of Patients (Dexmedetomidine) |
Number of Patients (Comparator) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|---|---|
|
31% |
N/A |
N/A |
Infants, children, and adolescents |
IV: Low dose |
Sedation for magnetic resonance imaging |
42 |
N/A |
N/A |
|
26% |
N/A |
N/A |
Infants, children, and adolescents |
IV: Middle dose |
Sedation for magnetic resonance imaging |
42 |
N/A |
N/A |
|
16% |
N/A |
N/A |
Infants, children, and adolescents |
IV: High dose |
Sedation for magnetic resonance imaging |
38 |
N/A |
N/A |
|
5% |
N/A |
0% |
Adults |
Sublingual film: 180 mcg |
Acute treatment of agitation associated with schizophrenia or bipolar I or II disorder |
252 |
N/A |
252 |
|
5% |
N/A |
0% |
Adults |
Sublingual film: 120 mcg |
Acute treatment of agitation associated with schizophrenia or bipolar I or II disorder |
255 |
N/A |
252 |
|
28% |
N/A |
13% |
Adults |
IV |
Intensive care unit sedation |
387 |
N/A |
379 |
|
24% |
Propofol: 13% |
12% |
Adults |
IV: 0.5 mcg/kg/hour (range: 0.1 to 6 mcg/kg/hour) |
Intensive care unit sedation |
798 |
188 |
400 |
|
56% |
Midazolam: 56% |
N/A |
Adults |
IV |
Long-term intensive care unit sedation |
244 |
122 |
N/A |
|
54% |
N/A |
30% |
Adults |
IV: 1.3 mcg/kg/hour (range: 0.3 to 6.1 mcg/kg/hour) |
Procedural sedation |
318 |
N/A |
113 |
Gastrointestinal: Constipation (6% to 14%), nausea (IV: 3% to 11%; sublingual: 3%)
Nervous system: Agitation (5% to 14%), drowsiness (including fatigue and lethargy: sublingual: 22% to 23%)
Respiratory: Bradypnea (infants, children, and adolescents: 58% to 79%), hypoxia (infants, children, and adolescents: 3% to 14%), respiratory depression (37%)
1% to 10%:
Cardiovascular: Atrial fibrillation (2% to 9%), edema (2%), orthostatic hypotension (sublingual: 3% to 5%), peripheral edema (3% to 7%)
Endocrine & metabolic: Hyperglycemia (7%), hypocalcemia (1%), hypoglycemia (5%), hypokalemia (9%), hypomagnesemia (1%), hypovolemia (3%), increased thirst (2%)
Gastrointestinal: Abdominal distress (sublingual: 2%), oral hypoesthesia (sublingual: ≤7%), xerostomia (IV: 3%; sublingual: 4% to 7%)
Genitourinary: Decreased urine output (1%), oliguria (2%)
Hematologic & oncologic: Anemia (3%)
Nervous system: Anxiety (5% to 9%), dizziness (sublingual: 4% to 6%), paresthesia (sublingual: ≤7%), withdrawal syndrome (ICU sedation; infants, children, and adolescents: 2%; adults: 3% to 5%)
Renal: Acute kidney injury (2% to 3%)
Respiratory: Acute respiratory distress syndrome (1% to 9%), pleural effusion (2%), respiratory failure (2% to 10%), wheezing (1%)
Miscellaneous: Fever (5% to 7%)
Postmarketing:
Cardiovascular: Acute myocardial infarction, atrioventricular block, cardiac arrhythmia, extrasystoles, inversion T wave on ECG, prolonged QT interval on ECG (IV, sublingual), sinoatrial arrest, supraventricular tachycardia, ventricular arrhythmia, ventricular tachycardia
Dermatologic: Hyperhidrosis, pruritus, skin rash, urticaria
Endocrine & metabolic: Acidosis, hyperkalemia, hypernatremia, respiratory acidosis
Gastrointestinal: Abdominal pain, diarrhea, gastrointestinal pseudo-obstruction (Alkaissi 2021), vomiting
Hematologic & oncologic: Hemorrhage
Hepatic: Abnormal liver function, hyperbilirubinemia, increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase
Nervous system: Anesthesia (light), chills, confusion, delirium, hallucination, headache, hyperpyrexia, illusion, neuralgia, neuritis, pain, seizure, speech disturbance
Ophthalmic: Photopsia, visual disturbance
Renal: Increased blood urea nitrogen, polyuria (Zhu 2022)
Respiratory: Apnea, bronchospasm, dyspnea, hypercapnia, hypoventilation, hypoxia, pulmonary congestion
Miscellaneous: Drug tolerance (use >24 hours) (Tobias 2010), tachyphylaxis (use >24 hours)
There are no contraindications listed in the US manufacturer's labeling.
Canadian labeling: Hypersensitivity to dexmedetomidine or any component of the formulation.
Disease-related concerns:
• Cardiovascular disease: Use IV formulation with caution in patients with heart block, bradycardia, severe ventricular dysfunction, hypovolemia, or chronic hypertension. In a scientific statement from the American Heart Association, dexmedetomidine has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]). Avoid use of the sublingual film in patients with hypotension, orthostatic hypotension, advanced heart block, severe ventricular dysfunction, history of syncope or other arrhythmias, symptomatic bradycardia, hypokalemia or hypomagnesemia, in patients at risk of torsades de pointes or sudden death, including those with known QT prolongation, and in patients receiving other drugs known to prolong the QT interval.
• Diabetes: Use with caution in patients with diabetes mellitus; cardiovascular adverse events (eg, bradycardia, hypotension) may be more pronounced.
• Hemodynamics: Bradycardia and/or hypotension may occur with loading doses. Transient, paradoxical hypertension may also occur with loading doses (ie, high peak plasma concentrations during rapid loading). Higher maintenance doses may cause bradycardia and hypertension, although hypotension may also occur (during titration or with dose escalations more frequently than every 30 minutes) (Ebert 2000; Gerlach 2009; Gerlach 2016; Tan 2010; Zhang 2016).
• Liver impairment: Use with caution in patients with liver impairment; dosage adjustment may be needed.
Special populations:
• Older adults: Use with caution in older adults; cardiovascular events (eg, bradycardia, hypotension) may be more pronounced. Dose reduction may be necessary.
Other warnings/precautions:
• Arousability: Patients may be arousable and alert when stimulated with use of the IV formulation. This alone should not be considered as lack of efficacy in the absence of other clinical signs/symptoms.
• Experienced personnel: IV formulation should be administered only by persons skilled in management of patients in intensive care setting or operating room. Patients should be continuously monitored.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Film, Sublingual, as hydrochloride:
Igalmi: 120 mcg (10 ea); 180 mcg (10 ea) [contains fd&c blue #1 (brilliant blue)]
Solution, Intravenous:
Generic: 400 mcg/4 mL (4 mL); 1000 mcg/10 mL (10 mL)
Solution, Intravenous, as hydrochloride:
Precedex: Dexmedetomidine 200 mcg/50 mL in NaCl 0.9% (50 mL); Dexmedetomidine 400 mcg/100 mL in NaCl 0.9% (100 mL)
Generic: 200 mcg/2 mL (2 mL); Dexmedetomidine 200 mcg/50 mL in NaCl 0.9% (50 mL); Dexmedetomidine 400 mcg/100 mL in NaCl 0.9% (100 mL)
Solution, Intravenous, as hydrochloride [preservative free]:
Precedex: 1000 mcg/250 mL (250 mL); 200 mcg/2 mL (2 mL); Dexmedetomidine 400 mcg/100 mL in NaCl 0.9% (100 mL [DSC]) [additive free, latex free]
Precedex: 80 mcg/20 mL (20 mL); Dexmedetomidine 200 mcg/50 mL in NaCl 0.9% (50 mL); Dexmedetomidine 400 mcg/100 mL in NaCl 0.9% (100 mL) [latex free]
Precedex: 80 mcg/20 mL (20 mL); 1000 mcg/250 mL (250 mL); Dexmedetomidine 200 mcg/50 mL in NaCl 0.9% (50 mL); Dexmedetomidine 400 mcg/100 mL in NaCl 0.9% (100 mL)
Generic: 80 mcg/20 mL (20 mL); 200 mcg/2 mL (2 mL); Dexmedetomidine 200 mcg/50 mL in Dextrose 5% (50 mL); Dexmedetomidine 200 mcg/50 mL in NaCl 0.9% (50 mL); Dexmedetomidine 400 mcg/100 mL in Dextrose 5% (100 mL); Dexmedetomidine 400 mcg/100 mL in NaCl 0.9% (100 mL)
May be product dependent
Film (Igalmi Sublingual)
120 mcg (per each): $126.00
180 mcg (per each): $126.00
Solution (dexmedeTOMIDine HCl in NaCl Intravenous)
80 mcg/20 mL (per mL): $1.63 - $1.71
200 mcg/50 mL (per mL): $0.28 - $1.08
400 mcg/100 mL (per mL): $0.23 - $1.00
Solution (dexmedeTOMIDine HCl Intravenous)
200 mcg/2 mL (per mL): $2.02 - $38.52
400MCG/4ML (per mL): $23.69
1000MCG/10ML (per mL): $15.99
Solution (dexmedeTOMIDine HCl-Dextrose Intravenous)
200MCG/50ML -5% (per mL): $0.46
400MCG/100ML -5% (per mL): $0.43
Solution (Precedex Intravenous)
80 mcg/20 mL (per mL): $1.59
200 mcg/2 mL (per mL): $3.60
200 mcg/50 mL (per mL): $0.67
400 mcg/100 mL (per mL): $0.60
1000MCG/250ML (per mL): $1.02
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous:
Precedex: 4 mcg/mL (20 mL, 50 mL, 100 mL)
Generic: 4 mcg/mL (50 mL, 100 mL, 250 mL)
Solution, Intravenous, as hydrochloride:
Precedex: 200 mcg/2 mL (2 mL)
Generic: 200 mcg/2 mL (2 mL)
IV: Administer using a controlled infusion device. Advisable to use administration components made with synthetic or coated natural rubber gaskets. If loading dose used, administer over 10 minutes; may extend to 20 minutes to further reduce vasoconstrictive effects. Titration no more frequently than every 30 minutes may reduce the incidence of hypotension when used for ICU sedation (Ref).
Sublingual film: For sublingual or buccal administration. Keep in foil pouch until ready to administer; administer immediately after pouch is open and dose is prepared. Remove from pouch with clean, dry hands. For half-doses, cut film in half between the dots with clean, dry scissors; discard the unused half in a waste container. For 60 mcg dose, cut 120 mcg film in half; for 90 mcg dose, cut 180 mcg film in half. For sublingual administration, place film under the tongue; for buccal administration place film behind the lower lip. Allow the film to dissolve; do not chew or swallow. Do not eat or drink for at least 15 minutes after sublingual administration, or at least one hour after buccal administration. Monitor vital signs. Patients should sit or lie down until vital signs are within normal range; if unable to remain seated or lying down, precautions should be taken to reduce the risks of falls. Ensure patient is alert and not experiencing symptomatic hypotension or orthostatic hypotension before resuming ambulation.
Parenteral:
IM: Administer undiluted (4 mcg/mL or 100 mcg/mL) into the deltoid or gluteal muscle (Ref).
IV: Concentrated solution (100 mcg/mL) must be diluted prior to administration; premixed IV solution (4 mcg/mL) is available. Administer using a controlled infusion device. Infuse loading dose over 10 minutes; may extend up to 20 minutes in neonatal patients or when needed to further reduce vasoconstrictive effects; rapid infusions are associated with severe side effects (Ref). Dexmedetomidine may adhere to natural rubber; use administration components made with synthetic or coated natural rubber gaskets.
Intranasal: Administer undiluted (100 mcg/mL) or dilute in a small volume of NS (eg, to a total volume of 1 or 1.5 mL). Divide dose and give half in each nostril by slowly dripping from a needleless syringe onto the nasal mucosa while in a recumbent position (Ref). Some recommend using a nasal atomizer such as the MAD Nasal Drug delivery device (Ref).
Oral: Administer parenteral formulation undiluted (100 mcg/mL) or diluted in ~5 mL of apple juice or honey (avoid use of honey in infants) (Ref).
IV infusion: 200 mcg in 50 mL (concentration: 4 mcg/mL) of NS
Note: Premixed solutions available.
IV infusion: 4 mcg/mL, 12 mcg/mL, 20 mcg/mL.
Agitation associated with schizophrenia or bipolar I or II disorder: Treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults.
Limitations of use: Safety and effectiveness have not been established beyond 24 hours from the first dose.
Procedural sedation or monitored anesthesia care (including flexible scope intubation [awake]): Procedural sedation in adults prior to and/or during awake fiberoptic intubation; sedation prior to and/or during surgical or other procedures of nonintubated adults; sedation prior to and/or during noninvasive procedures of nonintubated pediatric patients ≥1 month of age.
Sedation, critically ill: Sedation of intubated, mechanically ventilated adults in the ICU; sedation in adults during extubation and post extubation in the ICU.
General anesthesia, maintenance
DexmedeTOMIDine may be confused with dexAMETHasone.
Precedex may be confused with Peridex.
The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes (moderate sedation agent, IV) which have a heightened risk of causing significant patient harm when used in error (High-Alert Medications in Acute Care Settings).
Errors have occurred due to misinterpretation of dosing information; use caution. Maintenance dose expressed as mcg/kg/hour.
Substrate of CYP2A6 (Minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Alfuzosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Alizapride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Amifostine: Blood Pressure Lowering Agents may increase hypotensive effects of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider Therapy Modification
Amisulpride (Oral): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Amisulpride (Oral): May increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor
Androgens: Hypertension-Associated Agents may increase hypertensive effects of Androgens. Risk C: Monitor
Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor
Arginine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Articaine: May increase CNS depressant effects of CNS Depressants. Management: Consider reducing the dose of articaine if possible when used in patients who are also receiving CNS depressants. Monitor for excessive CNS depressant effects with any combined use. Risk D: Consider Therapy Modification
Azelastine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk X: Avoid
Barbiturates: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Benperidol: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Benperidol: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Beta-Blockers: May increase rebound hypertensive effects of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Alpha2-Agonists may increase AV-blocking effects of Beta-Blockers. Sinus node dysfunction may also be enhanced. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable. Risk D: Consider Therapy Modification
Blonanserin: CNS Depressants may increase CNS depressant effects of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider Therapy Modification
Blood Pressure Lowering Agents: May increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor
Bradycardia-Causing Agents: May increase bradycardic effects of Bradycardia-Causing Agents. Risk C: Monitor
Brimonidine (Topical): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Brimonidine (Topical): May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Bromopride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Bromperidol: May decrease hypotensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase hypotensive effects of Bromperidol. Risk X: Avoid
Bromperidol: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid
Buclizine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Buprenorphine: CNS Depressants may increase CNS depressant effects of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider Therapy Modification
BusPIRone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Cannabinoid-Containing Products: CNS Depressants may increase CNS depressant effects of Cannabinoid-Containing Products. Risk C: Monitor
Ceritinib: Bradycardia-Causing Agents may increase bradycardic effects of Ceritinib. Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy. Risk D: Consider Therapy Modification
Cetirizine (Systemic): May increase CNS depressant effects of CNS Depressants. Management: Consider avoiding this combination if possible. If required, monitor for excessive sedation or CNS depression, limit the dose and duration of combination therapy, and consider CNS depressant dose reductions. Risk D: Consider Therapy Modification
Chloral Hydrate/Chloral Betaine: CNS Depressants may increase CNS depressant effects of Chloral Hydrate/Chloral Betaine. Management: Consider alternatives to the use of chloral hydrate or chloral betaine and additional CNS depressants. If combined, consider a dose reduction of either agent and monitor closely for enhanced CNS depressive effects. Risk D: Consider Therapy Modification
Chlormethiazole: May increase CNS depressant effects of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider Therapy Modification
Chlorphenesin Carbamate: May increase adverse/toxic effects of CNS Depressants. Risk C: Monitor
CNS Depressants: May increase CNS depressant effects of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider Therapy Modification
Daridorexant: May increase CNS depressant effects of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider Therapy Modification
Diazoxide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Difelikefalin: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Dihydralazine: CNS Depressants may increase hypotensive effects of Dihydralazine. Risk C: Monitor
Dimethindene (Topical): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
DroPERidol: May increase CNS depressant effects of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider Therapy Modification
DULoxetine: Blood Pressure Lowering Agents may increase hypotensive effects of DULoxetine. Risk C: Monitor
Emedastine (Systemic): May increase CNS depressant effects of CNS Depressants. Management: Consider avoiding this combination if possible. If required, monitor for excessive sedation or CNS depression, limit the dose and duration of combination therapy, and consider CNS depressant dose reductions. Risk C: Monitor
Entacapone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Etrasimod: May increase bradycardic effects of Bradycardia-Causing Agents. Risk C: Monitor
Fexinidazole: Bradycardia-Causing Agents may increase arrhythmogenic effects of Fexinidazole. Risk X: Avoid
Fingolimod: Bradycardia-Causing Agents may increase bradycardic effects of Fingolimod. Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose. Risk D: Consider Therapy Modification
Flunarizine: CNS Depressants may increase CNS depressant effects of Flunarizine. Risk X: Avoid
Flunitrazepam: CNS Depressants may increase CNS depressant effects of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider Therapy Modification
Herbal Products with Blood Pressure Lowering Effects: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
HydrOXYzine: May increase CNS depressant effects of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider Therapy Modification
Hypotension-Associated Agents: Blood Pressure Lowering Agents may increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor
Ivabradine: Bradycardia-Causing Agents may increase bradycardic effects of Ivabradine. Risk C: Monitor
Ixabepilone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Kava Kava: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Ketotifen (Systemic): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Kratom: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid
Landiolol: Bradycardia-Causing Agents may increase bradycardic effects of Landiolol. Risk X: Avoid
Lemborexant: May increase CNS depressant effects of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider Therapy Modification
Levocetirizine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Levodopa-Foslevodopa: Blood Pressure Lowering Agents may increase hypotensive effects of Levodopa-Foslevodopa. Risk C: Monitor
Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may increase QTc-prolonging effects of Levoketoconazole. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor
Lisuride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Lofexidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Lormetazepam: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Loxapine: CNS Depressants may increase CNS depressant effects of Loxapine. Management: Consider reducing the dose of CNS depressants administered concomitantly with loxapine due to an increased risk of respiratory depression, sedation, hypotension, and syncope. Risk D: Consider Therapy Modification
Magnesium Sulfate: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Mequitazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Metergoline: May decrease antihypertensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase orthostatic hypotensive effects of Metergoline. Risk C: Monitor
Metergoline: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Methotrimeprazine: CNS Depressants may increase CNS depressant effects of Methotrimeprazine. Methotrimeprazine may increase CNS depressant effects of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider Therapy Modification
Metoclopramide: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
MetyroSINE: CNS Depressants may increase sedative effects of MetyroSINE. Risk C: Monitor
Midodrine: May increase bradycardic effects of Bradycardia-Causing Agents. Risk C: Monitor
Minocycline (Systemic): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Mirtazapine: May decrease antihypertensive effects of Alpha2-Agonists. Management: Consider avoiding concurrent use. If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased. Risk D: Consider Therapy Modification
Molsidomine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Moxonidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Nabilone: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid
Naftopidil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Nicergoline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Nicorandil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Nitroprusside: Blood Pressure Lowering Agents may increase hypotensive effects of Nitroprusside. Risk C: Monitor
Noscapine: CNS Depressants may increase adverse/toxic effects of Noscapine. Risk X: Avoid
Obinutuzumab: May increase hypotensive effects of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider Therapy Modification
Olopatadine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk X: Avoid
Opicapone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Opioid Agonists: CNS Depressants may increase CNS depressant effects of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider Therapy Modification
Opipramol: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Orphenadrine: CNS Depressants may increase CNS depressant effects of Orphenadrine. Risk X: Avoid
Oxomemazine: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid
OxyCODONE: CNS Depressants may increase CNS depressant effects of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider Therapy Modification
Ozanimod: May increase bradycardic effects of Bradycardia-Causing Agents. Risk C: Monitor
Paraldehyde: CNS Depressants may increase CNS depressant effects of Paraldehyde. Risk X: Avoid
Pentoxifylline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Periciazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Phosphodiesterase 5 Inhibitors: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Pipamperone: May increase adverse/toxic effects of CNS Depressants. Risk C: Monitor
Piribedil: CNS Depressants may increase CNS depressant effects of Piribedil. Risk C: Monitor
Ponesimod: Bradycardia-Causing Agents may increase bradycardic effects of Ponesimod. Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm. Risk D: Consider Therapy Modification
Pramipexole: CNS Depressants may increase sedative effects of Pramipexole. Risk C: Monitor
Procarbazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Prostacyclin Analogues: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may increase QTc-prolonging effects of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor
Quinagolide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Rilmenidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Ropeginterferon Alfa-2b: CNS Depressants may increase adverse/toxic effects of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider Therapy Modification
ROPINIRole: CNS Depressants may increase sedative effects of ROPINIRole. Risk C: Monitor
Rotigotine: CNS Depressants may increase sedative effects of Rotigotine. Risk C: Monitor
Serotonin/Norepinephrine Reuptake Inhibitor: May decrease therapeutic effects of Alpha2-Agonists. Risk C: Monitor
Silodosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor
Siponimod: Bradycardia-Causing Agents may increase bradycardic effects of Siponimod. Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring. Risk D: Consider Therapy Modification
Solriamfetol: May increase hypertensive effects of Hypertension-Associated Agents. Risk C: Monitor
Suvorexant: CNS Depressants may increase CNS depressant effects of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider Therapy Modification
Thalidomide: CNS Depressants may increase CNS depressant effects of Thalidomide. Risk X: Avoid
TiZANidine: Alpha2-Agonists may increase hypotensive effects of TiZANidine. Risk X: Avoid
Tricyclic Antidepressants: May decrease antihypertensive effects of Alpha2-Agonists. Management: Consider avoiding this combination. If used, monitor for decreased effects of the alpha2-agonist. Exercise great caution if discontinuing an alpha2-agonist in a patient receiving a TCA. Risk D: Consider Therapy Modification
Valerian: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor
Zolpidem: CNS Depressants may increase CNS depressant effects of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider Therapy Modification
Zuranolone: May increase CNS depressant effects of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider Therapy Modification
Dexmedetomidine crosses the placenta.
Placental transfer was demonstrated following IV infusion in patients undergoing cesarean delivery (Eskandr 2018; Wang 2017; Yu 2015). Based on data from human placental perfusion studies, dexmedetomidine may be retained in the placenta, partially limiting the total amount that could be transferred to the fetus (Ala-Kokko 1997).
Bradycardia is reported with dexmedetomidine use. Fetal bradycardia was noted following a maternal IV bolus dose administered during surgery to a patient on dexmedetomidine infusion for a percutaneous balloon mitral valvuloplasty at 27 weeks' gestation (Weiner 2014).
IV and intrathecal dexmedetomidine have been evaluated for use during spinal anesthesia in patients undergoing cesarean delivery (Bao 2017; Liu 2019; Shen 2020; Sun 2020; Wang 2019). Data from available meta-analyses of randomized controlled studies found no adverse effects of exposure on 1- and 5-minute Apgar scores or umbilical cord blood gases (Lee 2021; Shen 2020; Sun 2020; Zhang 2017). Decreased maternal shivering, nausea, and vomiting have been observed in some studies; dexmedetomidine may also improve the onset to anesthesia compared to some other agents (Bao 2017; Liu 2019; Shen 2020; Sun 2020; Wang 2019; Zhang 2017).
Dexmedetomidine (in combination with other agents) has also been evaluated for use in patient-controlled analgesia following cesarean delivery (Liu 2021; Nie 2018; Zhang 2021).
Dexmedetomidine is present in breast milk.
• A study to test a method of detecting dexmedetomidine in breast milk presented data collected following administration to 4 women undergoing cesarean delivery. Dexmedetomidine IV was given at 6 mcg/kg/hour for 10 minutes, followed by 0.2 to 0.7 mcg/kg/hour until closure of the peritoneal incision. Dexmedetomidine was present in maternal serum of all patients at the end of the infusion (range: 390.3 to 744 pg/mL). Breast milk and maternal serum were sampled 6 and 24 hours after the infusion stopped. Breast milk concentrations at 6 hours ranged from less than the level of detection (<3 pg/mL) to 30.4 pg/mL and all breast milk samples obtained at 24 hours were less than the level of detection. Using the data collected at 6 hours, authors of the study calculated the relative infant dose (RID) of dexmedetomidine to be <1% of the weight-adjusted maternal dose (range: 0.040% to 0.098%) (Nakanishi 2017).
• Dexmedetomidine was evaluated in the colostrum of 10 patients following cesarean delivery. Patients received dexmedetomidine 6 mcg/kg/hour over 10 minutes following removal of the neonate followed by a maintenance dose of 0.7 mcg/kg/hour until closure of the peritoneal incision (mean dose: 63 9 mcg over 21 ± 5 minutes). Maternal serum levels at the end of the infusion ranged from 293.5 to 744 pg/mL. Six hours following dexmedetomidine administration, breast milk concentrations ranged from below the limit of detection to 30.4 pg/mL. Only 1 sample had detectable concentrations at 12 hours (13.6 pg/mL) and dexmedetomidine was not measurable in any breast milk sample 24 hours after the dose. Authors of this study calculated the RID at 6 hours to be <1% of the weight-adjusted maternal dose (range: 0.023% to 0.098%). Breastfeeding was adequate for all neonates at 3 and 5 days, except for 1 infant at 3 days (Yoshimura 2017).
• The presence of dexmedetomidine in breast milk was evaluated in patients receiving patient-controlled IV analgesia (PCIA) following cesarean delivery. Following a bolus dose of 0.5 mcg/kg, pumps were programed to deliver dexmedetomidine 0.03 mcg/kg/hour (n = 29), 0.05 mcg/kg/hour (n = 29), or 0.08 mcg/kg/hour (n = 28) in combination with butorphanol. The basal infusion rate and bolus doses were the same for each study group. Breast milk was collected for 48 hours once lactation started. Dexmedetomidine was present at all doses evaluated. The highest concentrations were observed in patients receiving 0.08 mcg/kg/hour. Actual concentrations were not presented; however, authors of the study calculated the RID of dexmedetomidine to be <1% of the weight-adjusted maternal dose. In addition, the 0.05 mcg/kg/hour dose was found to be most effective for maternal analgesia (Liu 2021).
• A case report describes dexmedetomidine breast milk concentrations in a patient who underwent an awake left frontal craniotomy at 4 weeks postpartum. Dexmedetomidine 45 mcg was administered as a bolus injection followed by an infusion of 0.7 to 1 mcg/kg/hour during surgery. Breast milk was collected twice during surgery and twice after. Concentrations of dexmedetomidine in breast milk were 88 pg/mL ~2 hours after surgery was initiated, and 50 pg/mL ~4 hours into surgery (following a pause in the infusion). Following surgery, breast milk samples obtained in the recovery room were 89 pg/mL (48 minutes after discontinuation of infusion) and 15 pg/mL (4 hours after the dexmedetomidine infusion was stopped) (Dodd 2021).
• In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).
A randomized, prospective, double-blind study was conducted to evaluate the effect of dexmedetomidine on breastfeeding outcomes. Patients who planned to exclusively breastfeed for ≥3 months following an elective cesarean delivery were eligible. Dexmedetomidine was initiated following cutting of the umbilical cord with a loading dose of 0.5 mc/kg, followed by 0.5 mcg/kg/hour until surgery ended. Patients were then connected to a PCIA pump and given dexmedetomidine 2 mcg/kg in combination with sufentanil and dolasetron (n = 72). Outcomes were compared to patients receiving similar care, with the exception of dexmedetomidine (n = 72). The mean GA at delivery was 39.34 weeks and 39.03 for the dexmedetomidine and standard care groups, respectively (p = 0.038). The 1- and 5-minute Apgar scores and duration of surgery were similar for both groups. The time to first lactation was shorter and the probability of exclusively breastfeeding within 6 weeks postpartum was greater in the dexmedetomidine group. Milk volumes were similar on the first day postpartum, but greater on the second day in patients in the dexmedetomidine group. A neonatal behavioral neurological assessment conducted on days 1 and 2 of life showed no differences in neonatal outcomes (Wang 2020).
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Breastfeeding infants should be monitored for adverse events (eg, irritability), particularly following high maternal doses used for prolonged periods of time (Mitchell 2020; Mitchell 2021).
Level of sedation; heart rate, respiration, rhythm, blood pressure; pain control. Note: Dexmedetomidine causes minimal respiratory depression, inhibits salivation, and is analgesic-sparing.
Critically ill mechanically ventilated ICU patients: Assess and adjust sedation according to scoring system (Richmond Agitation-Sedation Scale [RASS] or Sedation-Agitation Scale [SAS]) (SCCM [Devlin 2018]).
Selective alpha2-adrenoceptor agonist with anesthetic and sedative properties thought to be due to activation of G-proteins by alpha2a-adrenoceptors in the brainstem resulting in inhibition of norepinephrine release; peripheral alpha2b-adrenoceptors are activated at high doses or with rapid IV administration resulting in vasoconstriction.
Onset of action:
IV loading dose: 5 to 10 minutes.
Intranasal:
Neonates (PMA: Median: 40.1 weeks): Median: 10 minutes (Bua 2018).
Infants: Median: 10 minutes (Yu 2017).
Children ≤12 years: Within 10 to 20 minutes (Miller 2018; Yu 2017).
Adults: 45 to 60 minutes (Yuen 2007).
Peak effect:
IV loading dose: 15 to 30 minutes.
IV continuous infusion: 60 minutes (Barr 2013).
Intranasal: 90 to 105 minutes (Yuen 2007).
Duration, post-continuous infusion (dose dependent): 60 to 240 minutes (Ebert 2000; Hall 2000; Ramsay 2004).
Distribution: IV: Vss:
Preterm Neonates (28 to <36 weeks GA): Median: 2.7 L/kg (range: 2.5 to 5.9 L/kg) (Chrysostomou 2014).
Term Neonates (36 to ≤44 weeks GA): Median: 3.9 L/kg (range: 0.1 to 10.9 L/kg) (Chrysostomou 2014). Neonates ≥36 weeks undergoing therapeutic hypothermia for hypoxic ischemic encephalopathy may have a larger volume of distribution (McAdams 2020).
Infants and Children <2 years: Median: 3.8 L/kg (range: 1.9 to 4.6 L/kg) (Vilo 2008).
Children 2 to 11 years: Median: 2.2 L/kg (range: 1.3 to 2.8 L/kg) (Vilo 2008).
Adults: ~118 L; rapid.
Bioavailability:
Intramuscular: 73% ± 11% (range: 54% to 91%) (Dyck 1993).
Intranasal: Variable: Median: 65% (range: 35% to 93%) (Iirola 2011).
Oral: 16% (range: 12% to 20%) (Anttila 2003).
Sublingual: 72%.
Buccal: 82%.
Protein binding: IV: ~94%.
Metabolism: Hepatic via N-glucuronidation, N-methylation, and CYP2A6.
Half-life elimination:
Intramuscular: Terminal: 281 ± 177 minutes (range: 57 to 707 minutes) (Dyck 1993).
IV:
Preterm Neonates (28 to <36 weeks GA): Terminal: Median: 7.6 hours (range: 3 to 9.1 hours) (Chrysostomou 2014).
Term Neonates (36 to ≤44 weeks GA): Terminal: Median: 3.2 hours (range: 1 to 9.4 hours) (Chrysostomou 2014). Neonates ≥36 weeks undergoing therapeutic hypothermia for hypoxic ischemic encephalopathy may have a longer elimination half-life (McAdams 2020).
Infants and Children <2 years: Terminal: Median: 2.3 hours (range: 1.5 to 3.3 hours) (Vilo 2008).
Children 2 to 11 years: Terminal: Median: 1.6 hours (range: 1.2 to 2.3 hours) (Vilo 2008).
Adults: Distribution: ~6 minutes; Terminal: Approximately up to 3 hours (Venn 2002); significantly prolonged in patients with severe hepatic impairment (Cunningham 1999).
Sublingual/Buccal: 2.8 hours.
Time to peak, serum:
Intramuscular: 13 ± 18 minutes (range: 2 to 60 minutes) (Dyck 1993).
Intranasal: Median: 38 minutes (range: 15 to 60 minutes) (Iirola 2011).
Sublingual/Buccal: 2 hours.
Excretion: IV: Urine (95%); feces (4%).
Clearance: IV:
Note: Clearance following cardiac surgery was reduced by 27% in pediatric patients aged 1 week to 14 years (Potts 2009).
Preterm Neonates (28 to <36 weeks GA): Median: 0.3 L/hour/kg (0.2 to 0.4 L/hour/kg) (Chrysostomou 2014).
Term Neonates (36 to ≤44 weeks GA): Median: 0.9 L/hour/kg (0.2 to 1.5 L/hour/kg) (Chrysostomou 2014). Neonates ≥36 weeks undergoing therapeutic hypothermia for hypoxic ischemic encephalopathy may have lower clearance (McAdams 2020).
Infants and Children <2 years: Median: 1 L/hour/kg (0.85 to 1.66 L/hour/kg) (Vilo 2008).
Children 2 to 11 years: Median: 1 L/hour/kg (0.56 to 1.35 L/hour/kg) (Vilo 2008).
Adults: ~39 L/hour; Hepatic impairment (Child-Pugh class A, B, or C): Mean clearance values were 74%, 64%, and 53% respectively, of those observed in healthy adults.
Hepatic function impairment: Clearance and plasma protein binding are decreased in patients with hepatic impairment.
